190 related articles for article (PubMed ID: 38173190)
1. Phosphatidylserine enriched with polyunsaturated n-3 fatty acid supplementation for attention-deficit hyperactivity disorder in children and adolescents with epilepsy: A randomized placebo-controlled trial.
Rheims S; Herbillon V; Gaillard S; Mercier C; Villeuve N; Villéga F; Cances C; Castelnau P; Napuri S; de Saint-Martin A; Auvin S; Nguyen The Tich S; Berquin P; de Bellecize J; Milh M; Roy P; Arzimanoglou A; Bodennec J; Bezin L; Kassai B;
Epilepsia Open; 2024 Apr; 9(2):582-591. PubMed ID: 38173190
[TBL] [Abstract][Full Text] [Related]
2. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Gillies D; Leach MJ; Perez Algorta G
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007986. PubMed ID: 37058600
[TBL] [Abstract][Full Text] [Related]
3. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Gillies D; Sinn JKh; Lad SS; Leach MJ; Ross MJ
Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD007986. PubMed ID: 22786509
[TBL] [Abstract][Full Text] [Related]
4. The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension.
Manor I; Magen A; Keidar D; Rosen S; Tasker H; Cohen T; Richter Y; Zaaroor-Regev D; Manor Y; Weizman A
Eur Psychiatry; 2012 Jul; 27(5):335-42. PubMed ID: 21807480
[TBL] [Abstract][Full Text] [Related]
5. Safety of phosphatidylserine containing omega3 fatty acids in ADHD children: a double-blind placebo-controlled trial followed by an open-label extension.
Manor I; Magen A; Keidar D; Rosen S; Tasker H; Cohen T; Richter Y; Zaaroor-Regev D; Manor Y; Weizman A
Eur Psychiatry; 2013 Aug; 28(6):386-91. PubMed ID: 23312676
[TBL] [Abstract][Full Text] [Related]
6. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo-controlled study.
Bélanger SA; Vanasse M; Spahis S; Sylvestre MP; Lippé S; L'heureux F; Ghadirian P; Vanasse CM; Levy E
Paediatr Child Health; 2009 Feb; 14(2):89-98. PubMed ID: 19436468
[TBL] [Abstract][Full Text] [Related]
7. Polyunsaturated fatty acid supplementation for drug-resistant epilepsy.
Sarmento Vasconcelos V; Macedo CR; de Souza Pedrosa A; Pereira Gomes Morais E; Porfírio GJ; Torloni MR
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD011014. PubMed ID: 27536971
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial investigating the effects of PCSO-524, a patented oil extract of the New Zealand green lipped mussel (Perna canaliculus), on the behaviour, mood, cognition and neurophysiology of children and adolescents (aged 6-14 years) experiencing clinical and sub-clinical levels of hyperactivity and inattention: study protocol ACTRN12610000978066.
Kean JD; Camfield D; Sarris J; Kras M; Silberstein R; Scholey A; Stough C
Nutr J; 2013 Jul; 12():100. PubMed ID: 23866813
[TBL] [Abstract][Full Text] [Related]
9. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
[TBL] [Abstract][Full Text] [Related]
10. Omega-3/6 supplementation for mild to moderate inattentive ADHD: a randomised, double-blind, placebo-controlled efficacy study in Italian children.
Carucci S; Romaniello R; Demuru G; Curatolo P; Grelloni C; Masi G; Liboni F; Mereu A; Contu P; Lamberti M; Gagliano A; Zuddas A
Eur Arch Psychiatry Clin Neurosci; 2022 Dec; 272(8):1453-1467. PubMed ID: 35672606
[TBL] [Abstract][Full Text] [Related]
11. Which polyunsaturated fatty acids are active in children with attention-deficit hyperactivity disorder receiving PUFA supplementation? A fatty acid validated meta-regression analysis of randomized controlled trials.
Puri BK; Martins JG
Prostaglandins Leukot Essent Fatty Acids; 2014 May; 90(5):179-89. PubMed ID: 24560325
[TBL] [Abstract][Full Text] [Related]
12. Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder.
Bos DJ; Oranje B; Veerhoek ES; Van Diepen RM; Weusten JM; Demmelmair H; Koletzko B; de Sain-van der Velden MG; Eilander A; Hoeksma M; Durston S
Neuropsychopharmacology; 2015 Sep; 40(10):2298-306. PubMed ID: 25790022
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension.
Weiss MD; Cutler AJ; Kollins SH; Donnelly GAE
J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):610-622. PubMed ID: 34637343
[No Abstract] [Full Text] [Related]
15. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
16. Effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial.
Widenhorn-Müller K; Schwanda S; Scholz E; Spitzer M; Bode H
Prostaglandins Leukot Essent Fatty Acids; 2014; 91(1-2):49-60. PubMed ID: 24958525
[TBL] [Abstract][Full Text] [Related]
17. Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.
Rodríguez C; García T; Areces D; Fernández E; García-Noriega M; Domingo JC
Neuropsychiatr Dis Treat; 2019; 15():1193-1209. PubMed ID: 31190827
[No Abstract] [Full Text] [Related]
18. Effect of Long-Term Omega 3 Polyunsaturated Fatty Acid Supplementation with or without Multidomain Lifestyle Intervention on Muscle Strength in Older Adults: Secondary Analysis of the Multidomain Alzheimer Preventive Trial (MAPT).
Rolland Y; Barreto PS; Maltais M; Guyonnet S; Cantet C; Andrieu S; Vellas B
Nutrients; 2019 Aug; 11(8):. PubMed ID: 31426362
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of attention deficit hyperactivity disorder in children: results of a multicenter, randomized, double-blind, placebo-controlled clinical trial].
Zavadenko NN; Makushkin EV; Gaynetdinova DD; Kolokolov OV; Malinina EV; Antipenko EA; Sagutdinova ES; Khaletskaya OV; Dmitriev AV; Maslova NN; Mashin VV; Panteleeva MV
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11):62-68. PubMed ID: 36440779
[TBL] [Abstract][Full Text] [Related]
20. The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial.
Hirayama S; Terasawa K; Rabeler R; Hirayama T; Inoue T; Tatsumi Y; Purpura M; Jäger R
J Hum Nutr Diet; 2014 Apr; 27 Suppl 2():284-91. PubMed ID: 23495677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
